Takahiro Ebata

655 total citations
34 papers, 404 citations indexed

About

Takahiro Ebata is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Takahiro Ebata has authored 34 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Takahiro Ebata's work include Cancer Immunotherapy and Biomarkers (6 papers), Ovarian cancer diagnosis and treatment (6 papers) and Renal cell carcinoma treatment (4 papers). Takahiro Ebata is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Ovarian cancer diagnosis and treatment (6 papers) and Renal cell carcinoma treatment (4 papers). Takahiro Ebata collaborates with scholars based in Japan, United States and Germany. Takahiro Ebata's co-authors include Keiko Kawauchi, Yuichi Takiguchi, Shunichiro Iwasawa, Koichiro Tatsumi, Tsukasa Ishiwata, Hiroaki Hirata, Ryota Kurimoto, Yuji Tada, Keigo Araki and Kenji Tamura and has published in prestigious journals such as Annals of Oncology, Cellular and Molecular Life Sciences and Molecules.

In The Last Decade

Takahiro Ebata

34 papers receiving 397 citations

Peers

Takahiro Ebata

ONCOL

PRM

Sumegha Mitra United States

Eun Kyoung Jeon South Korea

En‐Hua Wang China

Shigenori Furukawa Japan

Yuichi Tsujimoto Japan

Isaiah G. Schauer United States

Ali Hussain United States

Hui Jun Lim Singapore

Éva Juhász Hungary

Sung Sun Kim South Korea

Sumegha Mitra United States

Takahiro Ebata

125 ×0.8

ONCOL

250 ×1.6

66 ×0.6

PRM

47 ×0.8

94 ×1.8

Citations per year, relative to Takahiro Ebata Takahiro Ebata (= 1×) peers Sumegha Mitra

Countries citing papers authored by Takahiro Ebata

Since Specialization

Citations

This map shows the geographic impact of Takahiro Ebata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takahiro Ebata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takahiro Ebata more than expected).

Fields of papers citing papers by Takahiro Ebata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takahiro Ebata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takahiro Ebata. The network helps show where Takahiro Ebata may publish in the future.

Co-authorship network of co-authors of Takahiro Ebata

This figure shows the co-authorship network connecting the top 25 collaborators of Takahiro Ebata. A scholar is included among the top collaborators of Takahiro Ebata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takahiro Ebata. Takahiro Ebata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kato, Mayumi Kobayashi, Yukihide Momozawa, Masaaki Komatsu, et al.. (2024). Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer. Cancer Science. 115(5). 1646–1655. 6 indexed citations

Hattori, Naoko, Satoshi Yamashita, Yuyu Liu, et al.. (2023). HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity. Breast Cancer Research and Treatment. 201(2). 317–328. 3 indexed citations

Kitano, Shigehisa, Yutaka Fujiwara, Toshio Shimizu, et al.. (2022). A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 90(6). 523–529. 5 indexed citations

Ebata, Takahiro, Satoshi Yamashita, Hideyuki Takeshima, et al.. (2022). DNA methylation marker to estimate ovarian cancer cell fraction. Medical Oncology. 39(5). 78–78. 5 indexed citations

Ebata, Takahiro, Satoshi Yamashita, Hideyuki Takeshima, et al.. (2022). DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer. Gynecologic Oncology. 167(3). 513–518. 4 indexed citations

Saito, Go, Takahiro Ebata, Tsukasa Ishiwata, et al.. (2021). Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents. Supportive Care in Cancer. 29(7). 4081–4088. 3 indexed citations

Kitano, Shigehisa, Toshio Shimizu, Takafumi Koyama, et al.. (2020). Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 87(1). 53–64. 8 indexed citations

Ebata, Takahiro, Kan Yonemori, Tadaaki Nishikawa, et al.. (2020). Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. Oncology. 98(10). 699–705. 8 indexed citations

Itoh, Katsuhiko, Takahiro Ebata, Hiroaki Hirata, et al.. (2019). DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death. Molecules. 24(17). 3175–3175. 8 indexed citations

10.

Ebata, Takahiro, Toshio Shimizu, Takafumi Koyama, et al.. (2019). Improved survival among patients enrolled in oncology phase 1 trials in recent decades. Cancer Chemotherapy and Pharmacology. 85(2). 449–459. 1 indexed citations

11.

Yunokawa, Mayu, Takahiro Ebata, Mayumi Kobayashi Kato, et al.. (2019). Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study. International Journal of Clinical Oncology. 24(9). 1111–1118. 6 indexed citations

12.

Ebata, Takahiro, Tatsunori Shimoi, Mototaka Miyake, et al.. (2018). Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor. Oncology. 94(6). 340–344. 17 indexed citations

13.

Ebata, Takahiro, Mayu Yunokawa, Hiroshi Yoshida, et al.. (2017). The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. International Journal of Gynecological Cancer. 27(9). 1850–1855. 5 indexed citations

14.

Ebata, Takahiro, Tatsunori Shimoi, Tsukasa Ishiwata, et al.. (2017). Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma. Oncology. 93(3). 177–182. 4 indexed citations

15.

Kurimoto, Ryota, Takahiro Ebata, Shunichiro Iwasawa, et al.. (2017). Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. Oncology Letters. 14(1). 944–950. 33 indexed citations

16.

Ebata, Takahiro, Mayu Yunokawa, Akihiko Shimomura, et al.. (2016). Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. Cancer Chemotherapy and Pharmacology. 78(6). 1283–1288. 11 indexed citations

17.

Ebata, Takahiro, Tatsunori Shimoi, Mayu Yunokawa, et al.. (2016). Efficacy of amrubicin monotherapy after platinum chemotherapy for non-gastrointestinal extrapulmonary neuroendocrine carcinoma. Annals of Oncology. 27. vi147–vi147. 1 indexed citations

18.

Kurimoto, Ryota, Shunichiro Iwasawa, Takahiro Ebata, et al.. (2016). Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. International Journal of Oncology. 48(5). 1825–1836. 61 indexed citations

19.

Yunokawa, Mayu, Takahiro Ebata, Akihiko Shimomura, et al.. (2016). Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemotherapy and Pharmacology. 78(4). 745–752. 9 indexed citations

20.

Sakaida, Emiko, Shunichiro Iwasawa, Ryota Kurimoto, et al.. (2016). Safety of a short hydration method for cisplatin administration in comparison with a conventional method—a retrospective study. Japanese Journal of Clinical Oncology. 46(4). 370–377. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact